Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.5K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Clinically Interpretable AI System for Real-Time Quality Control of Transthoracic Echocardiography: Development, Validation, and Deployment.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2026
Same author

Privacy-Preserving Federated Deep Learning for Robust Anomaly Detection in Distributed Security Sensing Systems.

Sensors (Basel, Switzerland)·2026
Same author

Alternative splicing of WRKY55 orchestrates ABA signaling to enhance plant stress resistance.

Plant physiology·2026
Same author

Targeting S100A8/A9 Ameliorates Heart Failure with Preserved Ejection Fraction by Modulating TLR4/NF-κB-Mediated Inflammation.

Clinical and experimental pharmacology & physiology·2026
Same author

A case report of bevacizumab-induced subcapsular renal hemorrhage in a patient with lung adenocarcinoma.

Frontiers in oncology·2026
Same author

Strengths for adaptation: The roles of multidimensional social support and resilience in shaping loneliness trajectories among rural left-behind children.

Applied psychology. Health and well-being·2026

Related Experiment Video

Updated: Jun 24, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419

KIAA1429 Induces m6A Modification of LINC01106 to Enhance the Malignancy of Lung Adenocarcinoma Cells via the

Di Xu1, Ziming Wang1, Fajiu Li2

  • 1Department of Pulmonary and Critical Care Medicine, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan 430015, Hubei, China.

Critical Reviews in Immunology
|June 7, 2024
PubMed
Summary

The KIAA1429 protein enhances N6-methyladenosine (m6A) modification of the LINC01106 long noncoding RNA (lncRNA), promoting lung adenocarcinoma (LUAD) progression. This discovery offers a potential therapeutic target for LUAD treatment.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

Related Experiment Videos

Last Updated: Jun 24, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

Area of Science:

  • Molecular Oncology
  • Epigenetics
  • RNA Biology

Background:

  • The long noncoding RNA (lncRNA) LINC01106 is critical for tumor cell malignancy.
  • Understanding LINC01106 mechanisms and clinical impact in lung adenocarcinoma (LUAD) is limited.
  • This study investigates the role of KIAA1429-mediated N6-methyladenosine (m6A) modification in LINC01106 expression during LUAD progression.

Purpose of the Study:

  • To elucidate the mechanism by which KIAA1429 influences LINC01106 expression in LUAD.
  • To determine the functional and clinical significance of the KIAA1429-m6A-LINC01106 axis in LUAD.
  • To explore the potential of targeting this pathway for LUAD therapy.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting to assess gene and protein expression.
  • In vitro assays (Transwell, EdU, CCK-8) to evaluate cell proliferation, invasion, and migration.
  • In vivo xenograft models to confirm the role of LINC01106 in tumor growth.
  • Methylated RNA immunoprecipitation (MeRIP) and actinomycin D assays to investigate RNA modification and stability.

Main Results:

  • LINC01106 and KIAA1429 were significantly upregulated in LUAD tissues and correlated with advanced tumor grade, stage, and poor prognosis.
  • LINC01106 inhibition suppressed LUAD cell proliferation, invasion, migration, and tumorigenicity.
  • KIAA1429 enhanced LINC01106 m6A modification and expression, thereby promoting LUAD malignancy and reversing the suppressive effects of LINC01106 silencing.
  • Silencing LINC01106 reduced phosphorylation of key proteins in the JAK/STAT3 pathway (JAK2, STAT3).

Conclusions:

  • KIAA1429 promotes LUAD development by enhancing LINC01106 m6A modification and expression.
  • The KIAA1429-m6A-LINC01106 pathway plays a crucial role in LUAD progression.
  • This pathway represents a promising therapeutic target for lung adenocarcinoma.